NCT06630845

Comparison of Whole Body DWI to FDG PET

Comparison of Whole Body DWI to FDG PET Using PET/MRI

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.

Detailed description

PRIMARY OBJECTIVE: I. Correlation of DWI and FDG to detect disease. SECONDARY OBJECTIVE: I. Inter-reader variability of DWI interpretation by region. OUTLINE: Participants will be imaged at a single timepoint using whole body DWI concurrent with FDG PET/MRI within 60 days of receiving a non-FDG PET (either PET/CT or PET/MRI). There will be an optional PET/MRI performed within six months of the original study. Participants will be followed up through a medical records review for up to two years.

Conditions

• Metastatic Cancer

Interventions

Type	Name	Description
DRUG	Fluorodeoxyglucose F18	Given IV as part of routine imaging
PROCEDURE	Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI)	Imaging procedure
PROCEDURE	Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI)	Imaging procedure done concurrently with PET/MRI
DEVICE	General Electric (GE) SIGNA PET/MR	Imaging device

Timeline

• Start date: 2025-02-06
• Primary completion: 2027-10-31
• Completion: 2029-10-31
• First posted: 2024-10-08
• Last updated: 2026-04-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study